IPF

GALACTIC-1


IPF Study

Study Title

A randomised, double-blind, multicentre, parallel, placebo-controlled, Phase IIb study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks

Study duration

13 months

Number of CLINIC VISITS

8 clinic visits

NUMBER OF PHONE CALLS

1 phone call

Main entry criteria
  • You are 40 years of age or older
  • You have been diagnosed with idiopathic pulmonary fibrosis (IPF) within the past 5 years

There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.

Assessments
  • Chest CT Scan
  • Questionnaires
  • ECGs
  • Breathing tests
  • Blood tests

You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $50 per visit for your time and travel.

AGN120-1


IPF Study

Study Title

An open label study of the efficacy, safety and tolerability of NP-120 on idiopathic pulmonary fibrosis and its associated cough

Study duration

13 weeks

Number of CLINIC VISITS

7 clinic visits

Main entry criteria
  • Diagnosed with idiopathic pulmonary fibrosis (IPF) within the past 7 years
  • Currently cough

There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.

Assessments
  • Questionnaires
  • Blood pressure and pulse
  • ECGs
  • Breathing tests
  • Blood tests
  • Cough count monitoring

You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $50 per visit for your time and travel.

Loading...